JD CPA - Kiromic Biopharma CEO Director
| KRBPDelisted Stock | USD 2.68 0.07 2.55% |
Insider
JD CPA is CEO Director of Kiromic Biopharma
| Age | 55 |
| Phone | 832 968 4888 |
| Web | https://www.kiromic.com |
Kiromic Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.9194) % which means that it has lost $0.9194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.2981) %, meaning that it created substantial loss on money invested by shareholders. Kiromic Biopharma's management efficiency ratios could be used to measure how well Kiromic Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Kiromic Biopharma currently holds 9.41 M in liabilities with Debt to Equity (D/E) ratio of 0.21, which may suggest the company is not taking enough advantage from borrowing. Kiromic Biopharma has a current ratio of 1.32, which is within standard range for the sector. Note, when we think about Kiromic Biopharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| Jason Davis | Virax Biolabs Group | 52 | |
| MPA MD | Unicycive Therapeutics | 51 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Samuel MD | Altamira Therapeutics | 71 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Annie Rasmussen | Allarity Therapeutics | 67 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Gabriel BA | Immix Biopharma | 37 | |
| Nandan BS | Immix Biopharma | 62 | |
| MBA MD | Immix Biopharma | 49 | |
| Jean Lechance | Altamira Therapeutics | N/A | |
| Peter Facchini | Enveric Biosciences | 60 | |
| James JD | Allarity Therapeutics | 55 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
Management Performance
| Return On Equity | -11.3 | ||||
| Return On Asset | -0.92 |
Kiromic Biopharma Leadership Team
Elected by the shareholders, the Kiromic Biopharma's board of directors comprises two types of representatives: Kiromic Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kiromic. The board's role is to monitor Kiromic Biopharma's management team and ensure that shareholders' interests are well served. Kiromic Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kiromic Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Ryan, Chief Officer | ||
| Leonardo Mirandola, Chief Officer | ||
| JD CPA, CEO Director | ||
| Daniel Clark, Chief Officer | ||
| MD PharmD, Chief Staff |
Kiromic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kiromic Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.3 | ||||
| Return On Asset | -0.92 | ||||
| Current Valuation | 9.55 M | ||||
| Shares Outstanding | 1.18 M | ||||
| Shares Owned By Insiders | 3.91 % | ||||
| Shares Owned By Institutions | 68.00 % | ||||
| Number Of Shares Shorted | 45.74 K | ||||
| Price To Book | 15.11 X | ||||
| EBITDA | (29.44 M) | ||||
| Net Income | (34.73 M) |
Pair Trading with Kiromic Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kiromic Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiromic Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Kiromic Stock
Moving against Kiromic Stock
| 0.67 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.67 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.63 | VCYT | Veracyte | PairCorr |
| 0.48 | VERA | Vera Therapeutics | PairCorr |
| 0.46 | DMAC | DiaMedica Therapeutics Upward Rally | PairCorr |
The ability to find closely correlated positions to Kiromic Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kiromic Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kiromic Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kiromic Biopharma to buy it.
The correlation of Kiromic Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kiromic Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kiromic Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kiromic Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Kiromic Stock
If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |